California-based Signostics, Inc. has launched SpeqViewTM, billed as the world's smallest and most cost-effective veterinary ultrasound device.
Using MotionScape and SectorView technology, and offering multiple transducer frequencies, the SpeqView delivers high-resolution images for key veterinary applications including: cystocentesis; bladder volume; foreign object localization; abdominal imaging; and musculo-skeletal diagnosis.
Jeff Green, Signostics Vice-President of Sales and Marketing said: "The SpeqView provides a break-through for veterinary practices. For the first time there is an ultrasound device that is highly portable, simple to use and individually affordable. The SpeqView improves veterinary practice efficiency and income by allowing immediate diagnosis in the consulting room, or in the field and by providing better animal care.
He added: "Weighing a little over half a pound, the SpeqView features extended battery life and amazing portability, and is worn around your neck like a stethoscope or placed in your pocket until the next use."
The SpeqView is configured to use 3.5MHz and 7.5MHz transducers and comes with a comprehensive warranty, which covers the system and transducers and eliminates the need for annual service contracts. Signostics also offers extensive training and education programs delivered on site, online and in collaboration with leading veterinary institutions and educators. No interest, twelve-month financing is available.
For more information visit www.SpeqView.com or contact Signostics on 001 877 5744667.
A campaign to reform English libel law to allow for robust criticism of scientific and medical claims without fear of legal action has been launched by journalist and author Simon Singh. It's a campaign which anyone working in the caring professions might wish to support.
The campaign comes as a consequence of legal action taken against Mr Singh by The British Chiropractic Association, which took exception (perhaps unsurprisingly) to an article he'd written in The Guardian. In the article, Mr Singh denounced claims on the BCA website that its members could use spinal manipulation to treat children with colic, ear infections, asthma, sleeping and feeding conditions, and prolongued crying as 'bogus', and criticised the BCA for 'happily promoting' these claims.
Out of curiosity, VetSurgeon rang the BCA press office this morning, and asked to be given the references for studies which it feels would support the original claims made on its site. Non have been forthcoming so far, which is a surprise. Under the circumstances, we'd have expected the BCA would have a raft of supporting evidence readily available.
But this isn't really about whether or not chiropractic works or not. The case seems to hinge upon whether Mr Singh's article implied that the BCA was being deliberately dishonest, or just delusional. He say's the latter. Unfortunately for him, Mr Justice Eady recently ruled the former, leaving Mr Singh with a bill for £100,000 worth of legal fees.
Mr Singh is to appeal. At stake is the freedom to be able to challenge scientific claims without fear of being sued. If you'd like to support this campaign, visit senseaboutscience.com and add your name to the 7000 others (including some pretty illustrious names) who have already done so.
Ceva Animal Health has added to its joint care range with the launch of Meloxidyl Oral Suspension for Cats, licensed for the treatment of musculoskeletal disorders and alleviation of post-operative pain.
Meloxidyl Oral Suspension for Cats is available in 15ml bottles containing 0.5mg/ml meloxicam. Each pack contains a tailored maintenance dosing syringe with a 'kg scale' for all sizes of cat. In addition, Meloxidyl's sweet tasting formulation helps to maximise ease of administration.
Meloxidyl Injection complements Ceva Animal Health's joint care range, which also includes Meloxidyl Injection for dogs and cats and Meloxidyl Oral Suspension for dogs.
For further information, please contact your Ceva Animal Health representative or call 01494 781510.
The new programme includes ten days of practical imaging sessions based at CPD Solutions' training centre in Studley near Birmingham, where participants will develop their existing imaging skills and learn additional techniques that they can use directly in small animal practice.
CPD Solutions says its PgCerts have unique benefits and key differences from other PgCert options available to vets, namely a strong emphasis on practical training (all attendance days are practical, with no lecture days), the way the attendance days are grouped into three sessions for convenience, and the 12 month duration of the programme.
Susie Coughlan, veterinary surgeon and MD at CPD Solutions has 21 years’ experience in providing practical training for vets. ‘Our experience is that vets get the most out of hands-on practical training in a structured and supportive environment, combined with reflective application of their new skills in practice. The new PgCert in Small Animal Diagnostic Imaging follows the same format – all attendance sessions are practical, and the course provides support for developing reflective work based learning that vets can use with all of their patients.’
For more information, contact CPD Solutions on 0151 328 0444 or visit www.pgcert.com
Novartis Animal Health has announced the launch of a campaign to improve awareness of and improve education about atopic dermatitis (AD), to coincide with the 10th anniversary of Atopica.
As part of the campaign, the company is inviting veterinary surgeons to take part in an online survey for the chance to win an iPad mini: www.surveymonkey.com/s/atopica
In addition, Novartis says it will be offering all sorts of new educational materials for both vets and owners, including research into current trends and attitudes towards AD, insights from experts in the field, and case studies.
Ricardo Garvao, Category Manager for Atopica said: "This year marks an important milestone for the Atopica brand that wouldn't have been possible without the backing of so many vets. Continued investment by Novartis Animal Health into research and education seems a fitting way to extend thanks for this support and so forms one of the key elements of the 'Decade of Comfort' campaign. I am constantly amazed at just how dedicated and hard-working vets are and am immensely proud that Novartis Animal Health shares their goal to help pets remain happy and healthy."
Ceva Animal Health has launched a new broad-spectrum, flavoured endoparasiticide tablet, Milbactor for dogs.
Milbactor contains milbemycin oxime and praziquantel, which offer protection against the common nematodes seen in the UK and the main species of tapeworm.
Milbemycin oxime treats Toxocara canis and Toxascaris leonina, Angiostrongylus vasorum and Crenosoma vulpis, the hookworm Ancylostoma caninum, the whipworm Trichuris vulpis and the eyeworm, Thelazia callipaeda. Milbactor also prevents heartworm disease caused by Dirofilaria immitis.
Praziquantel protects against Echinococcus spp., Dipylidium caninum, Taenia spp. and Mesocestoides spp.
Puppies weighing more than 0.5 kg can be treated with Milbactor from two weeks of age. Milbactor comes in two tablet sizes for dogs and puppies, and the tablets are flavoured for easy administration.
Ceva has also launched The Ceva Protection System for dogs, a two-step solution featuring Vectra 3D and Milbactor to provide ectoparasite and endoparasite protection for dogs with one monthly topical treatment and one flavoured tablet. The Ceva Protection System uses Vectra Felis for flea protection for cats and Acclaim for the treatment of the pet's home environment.
Rob McLintock MRCVS, companion animal business unit manager at Ceva Animal Health, said: "The launch of Milbactor and The Ceva Protection System will enable veterinary surgeons to offer their clients a simple regime featuring Vectra 3D and Milbactor for comprehensive parasite control in dogs. Offering protection both inside and out and with no bite required to kill fleas, the regime offers a simple, effective combination to treat and prevent fleas, ticks, biting flies, roundworms, tapeworms, lungworms and to prevent heartworm.
For further information on The Ceva Protection System, Milbactor, Vectra 3D or Vectra Felis, contact your local Ceva territory manager or call 01494 781510.
The protocol provides evidence-based best practice criteria so that hospitals and other health settings can introduce animals into the care environment.
By following it, the RCN says services will be able to ensure the safety of patients and health care staff as well as the animals and their owners, while allowing patients to reap the benefits that interaction with animals can bring.
Publication of the protocol was prompted by an RCN survey last year which found that although the majority of respondents thought animals were hugely beneficial to patients, most nurses said animals were not allowed in their workplace.
The survey found that nine out of 10 nurses believe animals can help improve the health of patients with depression and other mental health problems with 60% of respondents also acknowledging that animals can help speed patient recovery.
Amanda Cheesley, RCN Professional Lead for Long-term Conditions and End-of-Life Care, said: "Anyone who’s worked in this area can see the amazing impact animals have on the health of adults and children alike.
"However there are so many myths around the dangers of having animals in health care settings that most organisations are too concerned to try it out.
"This protocol will help to dispel these fears by supporting hospitals to include animals in the care they deliver in a safe and professional way.
"We hope that it will encourage all health services to consider how animals can help their patients and help us to remove the taboo from what is a really remarkable area of care."
The protocol has been welcomed by the British Veterinary Association. Simon Doherty, BVA Junior Vice President, said: "This new protocol highlights the importance of the bond between humans and animals. It also serves as a welcome reminder at the start of Mental Health Awareness Week of how caring for and interacting with ‘man’s best friend’ can help to relieve stress and enhance wellbeing and a sense of companionship.
"It’s positive that the working group consulted with a wide range of organisations on welfare and safety considerations in developing this protocol, as ensuring the wellbeing of both humans and animals in these settings is paramount. As a fellow member of the UK One Health Coordination Group, BVA is very pleased to see a joined-up and forward-thinking approach to this important area of work."
Photo: Therapy Dog Visiting Young Female Patient In Hospital, Monkey Business Images / Shutterstock
The improvements include a new cat ward designed to offer a quieter, more relaxing area away from other animals, and a new walk-in dog ward which will allow staff to treat larger breeds of dogs more easily. The intensive care unit has been expanded and the practice has developed a new chemotherapy area.
John Turkington, the partner at Scarsdale Vets responsible for overseeing the work said: "We are already really proud of the state-of-the-art facilities we have at Pride, but we are not complacent and that is why we have made this significant investment to improve our facilities and ultimately the services we offer our clients and patients. Patient comfort is paramount, which is why we’ve invested in an additional walk in ward for our larger breeds, and a new cat ward with a separate feline examination and treatment area."
As well as the changes to improve clinical care, the practice has also invested in its kennelling services, increasing the number of 'suites' for cats and dogs to stay in its 'hotel' areas whilst their owners go on holiday.
John added: "We want Pride to be recognised as one of the best veterinary hospitals in Europe and to make that a reality we have increased our ward capacity for patient comfort and clinical treatment areas, as well as improving facilities behind the scenes for our staff, to create a better working environment. Alongside that the improvements to our Pet Resort will also meet the growing demands from clients for those services."
The competition is open to all UK-based undergraduate veterinary students and offers them the opportunity to work as a team to brainstorm, develop and present an innovative idea to a board of industry professionals.
Students can enter either as a single applicant or as a group (of roughly five members), with single applicants then being placed in a group with other applicants from their university. There can be more than one team representing each university.
Each student’s project can cover any aspect of veterinary health innovation. The RCVS suggests potential projects might include: innovations within veterinary education, innovations to improve sanitation and hygiene, innovations to improve veterinary-public communication and innovations to improve patient safety.
Entries must show how they have improved upon – or extended beyond – current expectations of best practice in their chosen area.
Each applicant will receive support from one of the Association of Veterinary Students’ (AVS) Vet Futures Ambassadors, as well as a mentor session with a chosen industry professional to guide them on their project.
Teams will need to submit three components for judging: a log of their progress throughout the project (which can include social media updates using the hashtag #ViVetStudentInnovation), mentor engagement and feedback, and a five-minute video ‘business pitch’.
The three finalist groups of the competition will be invited to present their pitch to a board of industry professionals at a ‘Dragon’s Den’ style event held at the RCVS ViVet 2019 Innovation Symposium on Tuesday 1 October 2019 in Manchester.
The winning and runner-up groups will then be selected and will be presented alongside the ‘mentor’s choice’ award. The Mentor’s Choice award will be selected by the team mentors. The prize will be awarded to an individual who shows excellence and enthusiasm within their work on the project.
Anthony Roberts, RCVS Director of Leadership & Innovation (pictured right), said: "This competition provides a great opportunity for veterinary students to engage with their fellow classmates across different fields of study and to work on projects that could genuinely make a difference to animal health and welfare and the way veterinary services are delivered. Teams will receive one-on-one mentoring and will be guided through the innovation process, developing skills that will be useful throughout their careers. We look forward to seeing the three finalist teams presenting at the RCVS ViVet Innovation Symposium in Manchester on 1 October."
Zoe Skinner, Vet Futures Student Representatives Team Leader, said: “This competition is a great opportunity for veterinary students to receive mentoring from experienced veterinary professionals and form contacts within our profession. It gives students a way to work together as a team and allows them to learn how to produce and develop innovative, problem-solving concepts as well as skills in delivering presentations. These are all important aspects of our career ahead, which will look brilliant on our CV’s.”
ViVet is now accepting registrations for the competition for the 2018/19 academic year. To enter, applicants must submit an online registration form. For further information, email info@vivet.org.uk.
Dr Kalisz faced a total of nine charges (including 41 sub-charges).
The first was that in July 2020, she failed to carry out a clinical examination of the dog, failed to adequately interpret test results, failed to ask for help interpreting the results, and undertook an emergency Caesarean section without sufficient need to do so.
The other charges related to undertaking a colotomy without sufficient justification and without exercising sufficient clinical judgment throughout the procedure.
For both the Caesarean section and the colotomy, Dr Kalisz faced charges that she failed to obtain informed consent from the owners and failed to inform them that the colotomy had been carried out, or of the potential risks of the procedure, and also failed to provide enough information about aftercare.
It was also alleged that Dr Kalisz had demonstrated continual lapses in professional judgement, including failing to appropriately manage the spaniel’s worsening condition when it was presented to the practice again later, and that the clinical records in relation to the surgery were dishonest and/or misleading.
Dr Kalisz admitted serious professional misconduct, admitting to 29 of the sub-charges, while the remaining 12 sub-charges were denied.
The Committee found 30 of the sub-charges proven, with the remaining 11 not proven.
The Committee the considered aggravating factors, including the fact that Dr Kalisz's conduct led to the spaniel’s death, the colotomy was reckless and Dr Kalisz did not take steps to inform anybody or make a clinical record for the colotomy.
In mitigation, the Committee considered the fact that it was single and isolated incident (albeit one that spanned a number of days), that no other members of the clinical team involved raised concerns during the procedure, and the effect Covid had upon the veterinary profession.
The Committee found that of those charges proven, the ones relating to performing the colotomy, failing to manage the spaniel’s subsequent care and failing to mention the colotomy amounted to serious professional misconduct.
On deciding the sanction, the Committee took into account the mitigation submitted on behalf of Dr Kalisz and the written testimonials produced including the fact that she was young and inexperienced, had admitted her failings at an early stage, had made subsequent efforts to avoid a repetition of such behaviour and that a significant amount of time had passed since the incident.
The Committee also considered that Dr Kalisz had shown an exemplary level of insight, showing remorse for her actions, undertaking substantial continuing professional development, and finding appropriate ongoing professional mentorship.
The Committee was impressed by the character testimonials from veterinary co-workers, both current and at the time of these events, as well as from clients.
It was, the Committee said, apparent from those testimonials that Dr Kalisz had been open and honest with them about the charges and was considered to be an excellent, committed veterinary surgeon.
Paul Morris, chairing the Committee and speaking on its behalf said: “The Committee found that this was a single isolated incident, which involved serious lapses of clinical judgement.
"It was therefore concluded that, despite Dr Kalisz’s actions being reckless, the extensive mitigation and the high level of insight, coupled with steps taken to avoid repetition, meant that there was negligible future risk to animal welfare.
“The Committee did not consider it necessary to issue a warning to Dr Kalisz about her future conduct, on the basis that the Committee has concluded that there is little risk of repetition, so considered that a reprimand would be an appropriate sanction in this case.”
https://www.rcvs.org.uk/concerns/disciplinary-hearings
Fort Dodge has released figures today which point to a continued modest slowdown in the UK veterinary sector, being mitigated by a slight increase in average transaction value (the amount a client spends in a year).
Matthew Rowe, Companion Animal Marketing Manager at Fort Dodge, said: "It's been clear for some time that the veterinary sector is being hit by static growth and an increasingly competitive environment. The reduction in turnover being experienced by many practices is primarily down to current clients visiting less often and fewer new clients being attracted."
Key findings of the Fort Dodge Index for the first quarter of 2009 are:
Alan Robinson said: "In the current climate, the only contributor to turnover growth in many practices seems to be a steady rise in the price of professional fees, consultations and surgery. These have continued to push up average transaction values (by 1.4%) and client values (1.2%) in this first quarter of 2009 despite reducing visit frequency. Drug related income increases seem to be driven by a small increase of POM mark-ups in many practices.
"But this alone will not sustain a successful business and, with transaction volumes still falling, the priority for practices is to maintain client footfall despite increasing competition and falling pet ownership. In today's market, retaining clients is a cheaper and more effective way to maintain client and patient numbers so an emphasis on 'bonding' clients though preventative health care and heath maintenance programmes is key.
"We're seeing a steady increase in the number of practices running these programmes but the percentage of pets involved is still woefully low so the message is that practices can and must do better.
The Blue Cross is calling for nominations from veterinary practices across the country for its Veterinary Nurse of the Year Award 2010.
The annual award is presented at the British Veterinary Nursing Association (BVNA) Annual Congress in October. It recognises the contribution of veterinary nurses in educating the public about responsible pet ownership and the welfare of pets in the community.
Last year's award was won by Vania Brasseleur for her outstanding contribution to animal welfare, both within her veterinary practice and among the local community in Newport Pagnell, Buckinghamshire
Vania was nominated for the award by student vet nurse and colleague Emily Martin at Astonlee Veterinary Hospital in Newport Pagnell.
Emily said: "Vania is committed to helping student nurses broaden their knowledge and help them on to the path to qualification. Her charity work, serving the public, helping colleagues and of course her nursing abilities are all truly fantastic! I don't think anybody could ask for a better nurse."
Nominations for this year's award can be made by completing the nomination form on The Blue Cross website at: www.bluecross.org.uk/BVNA2010 or by contacting Sally Leathem on 01993 825577. The deadline for nominations is Friday 20 August 2010.
Stronghold Plus contains the same selamectin found in common-or-garden Stronghold, licensed for the treatment of fleas, flea allergic dermatitis, ear mites (Otodectes cynotis), roundworm (Toxocara cati), intestinal hookworms (Ancylostoma tubaeforme), biting lice (Felicola subrostratus), and for the treatment of heartworm disease caused by Dirofilaria immitis.
To that has been added sarolaner, a new acaricide and insecticide which is also effective for five weeks against Ixodes ricinus, Ixodes hexagonus, and for four weeks against Dermacentor reticulatus and Rhipicephalus sanguineus.
Clint Lewis, Executive Vice President and President International Operations, said: "The launch of Stronghold Plus enables Zoetis to offer veterinarians in the European Union a new topical choice that treats the parasites commonly presenting a threat to cats with one convenient monthly dose.
For the first time, we have combined our new, versatile parasiticide sarolaner with the active ingredient in Stronghold, selamectin, resulting in the first approval of sarolaner for use in cats. We see sarolaner as a promising platform for future product lines and lifecycle innovations and are pleased with the positive data that sarolaner and its combination continue to generate in studies.”
Domenico Otranto, Professor of Parasitology at Bari University in Italy, who has reviewed the product data of Stronghold Plus, said: "A number of laboratory and field studies show the efficacy of the single spot-on application of Stronghold Plus for at least one month. Veterinarians in Europe now have a very effective option for the treatment and control of four prominent species of ticks commonly found on cats while maintaining proven efficacy against fleas, GI worms, heartworms, ear mites and lice. Ultimately, pet owners and practitioners have a new tool for improving health and welfare of cats."
Fergus Allerton has become the Editor-in-Chief for Part A: Canine and Feline, whilst Joanna Hedley is the Editor-in-Chief for Part B: Exotic Pets.
For both formularies, the editorial panels have reviewed the drug monographs to make sure all the information is up to date.
Part A includes:
Part B includes:
BSAVA President, Sue Paterson said: "The BSAVA Small Animal Formulary is recognised as an invaluable asset for the small animal clinician and is one of the Association’s most useful member benefits. Busy small animal clinicians in both primary care and referral practice will find this evidence-based resource an invaluable help with immediate prescribing advice."
Eligible BSAVA members will receive a complimentary print copy of Part A: Canine and Feline, and those who renew their membership in 2020 will also receive Part B: Exotic Pets as a loyalty reward gift.
Both Part A and Part B are available:
For more information, visit: https://www.bsava.com.
Animalcare's new Cephacare flavour antibiotic has received a response of 'good' or 'very good' in 80% of cases in a recent field study of superficial pyoderma in dogs. When asked to rate the effectiveness of the cephalexin-based antibiotic, more than half of the cases were awarded the highest response level of 'very good'.
Animalcare asked vets from across the country to participate in the study in order to confirm the company's own opinion. Each vet recorded five cases of superficial pyoderma in dogs and scored the effectiveness of treating the condition with Cephacare flavour. The first vets to complete their assessment forms received a free copy of the BSAVA Manual of Small Animal Dermatology worth £85.
The antibiotic proved effective across 19 different breeds, with animal weights ranging from 7kg to 70kg. Varying degrees of condition severity from mild through to severe were recorded with the average treatment length being 14-17 days. A number of 'severe' cases were treated with positive results. Severe was defined as long standing or recurrent areas of papules, crusting papules, epidermal collarettes and intact pustules.
Tony Liepman, Animalcare Market Manager, said: "A study like this confirms the product's effectiveness and, importantly, the acceptance of Cephacare flavour in real-world cases."
Mr Samuel had been removed from the Register in 2018 for causing unnecessary harm to numerous animals.
After being tried and convicted of several animal welfare offences alongside his former partner at Leeds Magistrates Court, Mr Samuel was sentenced to 12 weeks’ imprisonment, suspended for 12-months on the condition that he did 150 hours of unpaid work.
He was also ordered to pay a £100 fine and subjected to a disqualification order under the Animal Welfare Act for three years.
Mr Samuel’s application for restoration was based on the facts that he accepted the seriousness of his actions and that he did not challenge the DC’s 2018 decision.
The Committee also heard evidence that since his removal from the Register, Mr Samuel - who had run a first opinion veterinary practice for nine years prior to being struck off - has undertaken 340 hours of work experience with other veterinary surgeons and 20 hours of CPD.
Dr Samuel was represented by Counsel who outlined in his submissions to the Committee how Dr Samuel’s former partner had sole responsibility for the animals and that she was involved in rehoming dogs and cats and that their relationship was ‘stressful’, that this made Dr Samuel neglect his professional obligations, and that Dr Samuel was now in a different relationship and his life had been ‘transformed’ since his conviction.
The College opposed Dr Samuel being restored to the Register.
Ms Curtis, Counsel on behalf of the College, submitted to the Committee that Dr Samuel continued to represent a risk to the welfare of animals and that to allow him to be restored to the Register would undermine public confidence in the profession.
She explained that even though his sentence and Animal Welfare Act Disqualification Order had come to an end, and he was now legally able to own animals, this should not be equated with him now being fit to return to the Register.
Dr Austin Kirwan MRCVS, chairing the Committee, and speaking on its behalf, said: “Where a veterinary surgeon has shown himself to be capable of such indifference to the welfare of multiple animals, there remained, in the Committee’s view, a real risk of that indifference manifesting itself again.
"A registered veterinary surgeon is entrusted with the care of animals, often when they are at their most vulnerable, and sometimes for prolonged periods of time.
"Given the nature of the animal welfare offences committed by Dr Samuel, the Committee considered there would be a real and significant risk to animals if the high level of responsibility and trust that comes with registration were returned to him.
“For a veterinary surgeon, conduct involving neglect of animals is at the highest end of the spectrum of serious professional misconduct.
"For the reasons outlined above, the Committee considered Dr Samuel continued to represent a risk to animal welfare and thus allowing him to be restored to the Register would seriously undermine public confidence in the profession.
"For all these reasons the application to restore Dr Samuel to the Register is refused.”
The Committee’s full findings can be viewed at www.rcvs.org.uk/disciplinary
Jonathan Hill (UK Country Manager) said: “I’m delighted to announce that TVM UK is changing its name to Dômes Pharma.
"This will align with the other operating companies within the group.
"TVM UK has always been owned by the Dômes Pharma group, and since the start of our journey in the UK market we have been synonymous with expertise and outstanding levels of customer service in selected speciality segments of the animal health market and this won’t change.”
“Under the Dômes Pharma name we will continue to build and grow on this very strong foundation.
"I’m looking forward to working with the entire Dômes Pharma team as we increase our presence as a leading specialty pharmaceutical company, bringing our ethos to new speciality segments with innovative products and solutions for vets in the UK.
"Dômes Pharma remains a family-owned business, and the culture of the company really reflects this and we live by our values of kindness, boldness and responsibility.” https://www.domespharma.com https://www.tvm-uk.com
'FLUTD and Dysuria – a frustration for many and not just the cat' will be presented by Dr Hanne Friis Lund (DVM) from Idexx and Katy Smith from Royal Canin (pictured right).
Hanne will be talking about diagnostics, focusing on urine analysis and laboratory tests, whilst Katy will discuss nutritional management of the condition.
Hanne said: "Feline lower urinary tract disease is a very common condition in both male and female cats affecting 1-3% of cats every year.
"It goes without saying that FLUTD causes great discomfort and pain for the feline, which is why the webinar will explore how best to manage the condition from a nutritional point of view.
"From the innovative Haematuria Detection by Blücare litter granules which turn blue when a urinary condition is detected to the new urinary range kibble from Royal Canin’s Veterinary Health Nutrition, the webinar will be leaving no stone unturned."
To register for the webinar, go to: https://vetportal.royalcanin.co.uk/cpd/webinar/
People are invited to organise or join a walk to raise money for Canine Arthritis Management and its work to educate both dog owners and veterinary professionals about how even the smallest of changes can help to enhance the life of a dog with arthritis.
CAM highlights recent work from the Royal Veterinary College and University of Sydney through VetCompass, which highlighted some of the biggest welfare challenges facing our pet population including obesity, dental disease and osteoarthritis, with osteoarthritis identified as one of the most severe conditions.
Hannah said: "We need to start more conversations about arthritis; both dog owners and vets need to be more aware of the steps we can take to help prevent arthritis, and where dogs are affected, how we can take positive action to help them live fulfilled and comfortable lives."
Hannah says that arthritis is currently one of the biggest causes of owners choosing to euthanise their dogs, and she hopes that owners taking part in the walks will help spread the word that arthritis can be managed.
To find out more about the Big September Walks visit www.facebook.com/CAMBigSeptemberWalks
The organisations made a joint submission to the Migration Advisory Committee (MAC) as part of its review into the Shortage Occupation List which began in autumn 2018 and will report back in spring 2019.
The BVA and the RCVS had previously made calls for the profession to be added to the list in 2017 when the MAC held a call for evidence on the impact of the UK's exit from the EU on various professions. The latest submission is a development on this previous submission, focused on the need for the post-Brexit immigration system to recognise the issues affecting the veterinary workforce, which is already under-capacity, and reiterating its importance in areas such as public health, food safety, disease surveillance and control, education, research, clinical practice and animal welfare.
The submission details how the demand for veterinary services does not currently match supply and that the UK is therefore reliant on overseas registrants, particularly from the rest of the EU, who currently make up around 50% of new registrants in a given year.
The RCVS and BVA add that, in the post-Brexit immigration system, this reliance on overseas vets needs to be recognised by adding veterinary surgeons to the Shortage Occupation List, thus reducing the immigration requirements needed for overseas veterinary surgeons to live and work in the UK and streamlining the application process for employers.
Amanda Boag, RCVS President, said: "We wanted to use this submission as an opportunity to reiterate the circumstances currently facing the profession, particularly in light of the uncertainties around the UK’s exit from the EU and the impact this could have on the supply of veterinary workforce from the rest of the EU, which is crucially important in a number of areas. We need, therefore, for veterinary surgeons to be immediately added back to the list so that we can ensure that this flow of workforce continues and that animal health and welfare is protected.
"In the meantime we are continuing to work with BVA and the Department for Environment, Food and Rural Affairs (Defra) to look at how we can develop ‘home-grown’ veterinary capacity in the UK through expanding the UK veterinary education sector, increasing retention rates within the profession, and looking at how the veterinary team could be reformed to allow allied professionals, such as veterinary nurses, to take on extra tasks and free up veterinary time. However, these are all long-term projects and not quick fixes to the issues facing the profession."
As well as calling for a future immigration system to prioritise the veterinary profession, RCVS and BVA also recommend that veterinary employers be exempt from the Immigration Skills Charge to avoid additional barriers or burdens to the employment of overseas vets and recommend that there is no minimum earning cap for veterinary surgeons applying for work visas, on the basis that veterinary surgeons are "skilled professionals who may choose to work in the UK for reasons other than remuneration".
Simon Doherty, BVA President, said: "It is in MAC’s gift to reinstate vets on the Shortage Occupation List and this evidence makes a strong case for it to happen as quickly as possible.
"Vets deliver multiple benefits to animal health and welfare, public health and food safety, and they have a crucial role to play in future trade deals and keeping standards and confidence in UK exports high. The profession is also indebted to a high proportion of skilled EU vets who have chosen to make the UK their home and place of work.
"With this in mind, the future immigration system must be geared around preserving veterinary capacity rather than introducing new layers of bureaucracy or restrictions on flexible movement between roles. We have raised concerns that extending the Immigration Skills Charge to EU workers would hit some areas of the workforce disproportionately hard, particularly the abattoir industry where 95 per cent of Official Veterinarians hail from overseas.
"With uncertain times ahead and demand for some veterinary services predicted to spiral after Brexit, it has never been more pressing to take decisive action to safeguard against shortfalls in capacity and give a vital vote of confidence in the veterinary workforce."
To read the full submission, visit https://www.rcvs.org.uk/document-library/joint-rcvs-and-bva-submission-to-migration-advisory-committee/
Ceva Animal Health has announced the launch of Vectra Felis, a new spot-on flea treatment for cats.
The new product contains two active ingredients: dinotefuran and pyriproxyfen. The first is an adulticide which Ceva says kills fleas on contact, thereby stopping fleas biting before they die. The second ingredient is an Insect Growth Regulator (IGR) which prevents flea reproduction and adult flea emergence, so protecting the cat and its environment from future flea attacks.
According to the company, Vectra Felis ensures that over 95% of fleas are killed within two hours and the effects last for a month.
In addition, Ceva highlights the product's patented applicator, which has an elongated smooth tip for quick and easy application. The company says it also provides accurate dosing and facilitates clean administration as nothing comes out until the tube is squeezed. Kittens can be treated from seven weeks of age (weighing at least 0.6kg).
For further information on Vectra Felis, contact your local Ceva territory manager or call 01494 781510.
The BVA Board oversees the performance of the Association and is responsible for corporate and financial governance and for setting the BVA’s strategic direction. It consists of nine members: the three Officers of the BVA, four Directors appointed by BVA Council and up to 2 non-veterinary Directors appointed by the Board. The Chairman is elected by the Board.
Philip, a Bristol University Veterinary School graduate, spent seven years in mixed practice in Sussex, Kent and Suffolk before embarking on a career in the veterinary pharmaceutical industry.
He became CEO of Novartis Animal Health UK Ltd in 1996 (where, incidentally, he was ultimately responsible for signing up a wet-behind-the-ears PR consultant by the name of Arlo Guthrie and giving the go-ahead for the development of vetnurse.co.uk, which in turn led to the launch of vetsurgeon.org). In 2003 he became the company's Head of Global Marketing, and in 2005, Head of Global Business Development.
Philip has also run business elective training at the Royal Veterinary College, which has provided first-hand experience of the concerns and opportunities facing new graduates within a changing profession.
Gudrun Ravetz, President of the British Veterinary Association, said: "We are delighted to announce Philip Lowndes as the new Chairman of the BVA Board. His experience and expertise in business, knowledge of the veterinary profession and involvement with BVA will be of great value as we continue to grow our membership and expand our services and support for vets, especially during the uncertainty caused by Brexit."
Philip holds previous chair experience, as Chairman of the National Office of Animal Health (NOAH) between 1997-2004, and currently sits as Chairman of both the Novartis UK Pension Trustee Board and its Investment Committee. He joined BVA’s Board in 2013 and was re-elected by BVA Council for a second term in 2016. He will be taking over from Derek Williams, who stepped down in March after seven years of tireless work as Chairman.
Gudrun said: "I also want to take this opportunity to thank Derek Williams for all the hard work he has put in over many years. In his role as Chairman Derek’s experience and expertise have been vital in helping BVA grow as an organisation."
Philip said: "I am honoured to be elected as the next Chairman of the BVA and look forward to chairing the Board as it addresses the challenges ahead. The veterinary profession needs and deserves vibrant representation and it is the Board’s role to ensure that the organisation has the ability and the resources to achieve this to the benefit of our membership."
The BVA Board also gained a new non-veterinary Board Director, Steven Anderson Dixon, from April. Mr Dixon brings with him a successful career in newspaper and magazine publishing, which will be an asset as BVA consolidates and continues to develop its portfolio of veterinary journals.
The researchers say that research thus far has focused on developing treatments to manage idiopathic epilepsy and little attention has been given to the emotional and logistical challenges for owners managing their dog’s condition.
This study used semi-structured interviews to explore how owners’ lives were changed following their dogs’ diagnosis and glean in-depth insights into their lives.
The research discovered that following their dog’s initial seizure, all interviewees recalled feeling negative emotions such as being distraught, fearful or uncertain regarding their dog’s future and disease progression. Prior experience with canine epilepsy was rare, and owners were shocked and distressed by the appearance of their dog’s seizures.
Whilst many owners discussed a very emotionally close dog-owner bond, owning a dog with epilepsy had a significant impact on their lifestyle. Impacts affected many aspects of daily routines, and in some cases, owners’ jobs. The unpredictable and sometimes inconvenient timing of seizures negatively impacted owners’ sleep and wellbeing. This unpredictability also made some owners feel that they were living with “a ticking time bomb”.
Other limitations included strict daily medication schedules and difficulty finding assistance in caring for their dog. This, combined with a fear of leaving their dog unsupervised, had social implications in some instances and led to increased use of the Internet and online groups for peer support. Owners also reported that friends, family and colleagues did not always understand the magnitude of commitment required.
Amy Pergande, Small Animal Intern at the RVC and primary author of the study, said: "We are sincerely grateful to the owners who participated in this study for providing us with such detailed and often emotive accounts of their experiences. Many of the participants had willingly altered many aspects of their daily routine for their dogs, both socially and professionally, and sometimes at the expense of their own quality of life."
This research highlights that further consideration of these factors by veterinary professionals and the friends and families of owners of these dogs could improve owner quality of life and facilitate the provision of additional, much needed support.
Rowena Packer, Lecturer in Companion Animal Behaviour and Welfare Science and research lead in canine epilepsy at the RVC, said: "Epilepsy can be an extremely tough condition for owners to manage, where the love, time and money owners dedicate to their dogs is not necessarily matched by a significant improvement in their condition, with seizures often continuing unabated. Our study has revealed previously unrecognised or under-appreciated impacts that epilepsy introduced to these owners’ lives. Improved awareness and understanding of these challenges by veterinary professionals have the potential to improve communication with clients, to avoid owners feeling that social media is the only place they can go to feel supported and understood”.
These findings increase the understanding of the sometimes negative and often profound emotional effects and lifestyle changes experienced by owners managing a dog with idiopathic epilepsy. With better support and resources, the reported impacts could potentially be minimised to protect owner quality of life.
Zoe Belshaw, independent research collaborator, said: “The welfare of pets and their owners can be closely intertwined. This research exploring how owners’ lives change when their dogs develop epilepsy is another important piece in the jigsaw of understanding both what the veterinary profession can do to best support our clients, but also in starting to appreciate the substantial wider societal impacts of chronic ill health in our nations’ pets”.
The full paper is open access and available at: https://bmcvetres.biomedcentral.com/articles/10.1186/s12917-020-02669-w
Reference
Photo: The Melias Studio
Bordetella bronchiseptica is a clinically significant pathogen for canine infectious respiratory disease (CIRD), otherwise known as kennel cough, with 78.7% of dogs with acute respiratory signs testing positive for the bacteria1.
In the same study, 45.6% of clinically healthy dogs also tested positive for Bordetella bronchiseptica, illustrating that clinically healthy dogs can carry respiratory pathogens and could act as sources of infection for susceptible dogs1.
Administered via subcutaneous injection, Canigen Bb is an inactivated subunit vaccine which offers vets a new option when intra-nasal vaccination with a live aerosolised vaccine is not possible or preferred, for example when the dog is in contact with known immunocompromised individuals.
Licensed for use in dogs from 6 weeks of age, Canigen Bb extends protection against Bordetella bronchiseptica in dogs vaccinated with Canigen KC in the last 12 months for a further year with a single dose.
Canigen Bb is presented as a ready-to-use formula in a 10ml multi-dose bottle and can be stored at room temperature (2°C - 25°C) for up to 4 weeks once broached.
It can be administered concurrently (at the same time but separate injections) with Canigen DHP, Canigen DHPPi, Canigen Pi & Canigen Lepto 4.
Andrew Connolly, Marketing Director at Virbac, said: ‘It is our hope that Canigen Bb will increase the overall uptake of Bordetella bronchiseptica vaccination to provide increased protection against this widely prevalent and clinically significant disease’.
Zoetis has launched a 4ml vial of the antibiotic, Convenia.
Zoetis says Convenia gives veterinary surgeons control by providing an assured injectable treatment course, relieving clients of the burden of daily dosing. This avoids missed or mistimed doses, lost tablets, or courses stopped too soon, thereby eliminating a major reason for treatment failure, non-compliance. Poor compliance is also a significant factor in the development of antimicrobial resistance.
Convenia is licensed for skin, soft tissue and urinary tract infections in dogs and cats, as well as severe gingivitis/periodontitis in dogs (as an adjunct to mechanical or surgical periodontal therapy). A 4ml vial can treat up to 40kg of bodyweight, making it appropriate for treating cats and smaller dogs.
Zoetis says that the launch of the new vial demonstrates its commitment to the 'Respect Antibiotics' campaign launched last year. The Respect Antibiotics campaign encourages careful and informed selection of appropriate antibiotic therapies for the treatment of dogs and cats.
Product Manager, Andrew Page, said; "We are committed to encouraging responsible antibiotic usage, and reducing the incidence of antibiotic resistance. Non-compliance plays a key role in the development of antibiotic resistance and we hope that by making Convenia more accessible through the introduction of a 4ml vial we can help alleviate compliance issues."
For further details about Convenia please contact your Zoetis Account Manager.